03 Aug Biosimilar Commercialization: Getting it Right in the Patent Landscape
By Franco Pissani, Ph.D. After a couple of losses at Circuit Courts, Sandoz’s battle to invalidate both of Amgen’s patents on Enbrel has seemingly come to a dead-end after SCOPUS declined their petition to review the case. This 9-1 decision gives Amgen another decade of exclusivity for their blockbuster drug Enbrel. In a ...